Annotation Detail
Information
- Associated Genes
- TP53
- Associated Variants
-
TP53 DELETERIOUS MUTATION
TP53 DELETERIOUS MUTATION - Associated Disease
- sarcoma
- Source Database
- CIViC Evidence
- Description
- 19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)].
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1170
- Gene URL
- https://civic.genome.wustl.edu/links/genes/45
- Variant URL
- https://civic.genome.wustl.edu/links/variants/221
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Sarcoma
- Evidence Direction
- Supports
- Drug
- Pazopanib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26646755
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Pazopanib | Sensitivity | true |